Since the binding of GAS6 to AXL has been found to promote cancer progression and sdAb20 was predicted to interact with the GAS6 recognition site, we further evaluated the GAS6/AXL blocking capacity of sdAb20 in vitro using a competition assay. Here, GAS6 is linked to cancer.